サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1498369

グリコミクス/グリコバイオロジーの世界市場の評価：製品タイプ別、用途別、エンドユーザー別、地域別、機会、予測（2017年～2031年）

Glycomics/Glycobiology Market Assessment, By Product Type, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日: | 発行: Market Xcel - Markets and Data | ページ情報: 英文 228 Pages | 納期: 3～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.72円
グリコミクス/グリコバイオロジーの世界市場の評価：製品タイプ別、用途別、エンドユーザー別、地域別、機会、予測（2017年～2031年）
出版日: 2024年06月20日
発行: Market Xcel - Markets and Data
ページ情報: 英文 228 Pages
納期: 3～5営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のグリコミクス/グリコバイオロジーの市場規模は、2023年の19億2,000万米ドルから2031年に58億5,000万米ドルに達すると予測され、予測期間の2024年～2031年にCAGRで14.93%の成長が見込まれます。市場は近年大幅な成長を示しており、今後も力強い拡大ペースを維持すると予測されます。

研究者が糖鎖の複雑性や他の生体分子との相互作用を探求し続けていることから、糖鎖の異常構造やグリコシル化パターンは、自己免疫疾患、糖尿病、がんなどのさまざまな疾患との関連性が高まっています。その結果、グリコミクスという学問分野は、糖鎖の構造、機能、健康や疾患に対する影響を明らかにし、糖鎖の同定、管理、創薬の可能性を示唆することを目指しています。数多くの相互に関連する変数が、世界のグリコミクス市場の成長軌道を後押ししています。グリコミクスは、異常なグリコシル化パターンに関連する糖尿病やがんなどの疾患を診断および治療する可能性のある手段として大きな注目を集めています。このような最先端のツールにより、研究者は糖鎖の複雑性と、健康と疾患の両方におけるその機能的意義をさらに掘り下げることができます。

医療の方向性を左右するグリコミクスの重要性は、個別化医療へのパラダイムシフトによってさらに強調されています。糖鎖プロファイリングは、カスタマイズされた治療計画に合わせた知見を提供することで、医療介入の効果と精度を大幅に向上させる可能性を秘めています。医療に対する患者中心のアプローチは、患者中心の治療オプションに向けて前進する上で、グリコミクスがいかに重要であるかを示しています。急速に成長するバイオ製薬部門は、生物製剤の創薬に糖鎖解析がいかに重要であるかを認識しつつあります。例えば2024年1月30日、画期的なin situ近接ライゲーションアッセイに基づくソリューションのリーダーであるNavinci Diagnostics AB Corpと、革新的なプロテオミクスおよび糖鎖の研究ソリューションのパイオニアであるVector Laboratoriesは、契約締結を発表しました。この提携は、組織サンプル中のタンパク質のグリコシル化を初めて同定する革新的なバイオマーカー探索技術の創出を目指すものです。

医療支出の増加が市場を促進

世界の医療支出の着実な増加は、世界のグリコミクス市場に大きなブームをもたらしています。公的機関も営利団体も医療の研究開発プロジェクトに多くの資金を拠出しており、それがグリコミクスのような分野への投資を後押ししています。さまざまな生物学的プロセスにおける糖鎖の重要な機能と、ヒトの健康への影響に関する理解の向上は、資金拠出の増加に反映されています。複雑な疾患の理解と治療が重視されるようになり、その多くが糖鎖に関連したプロセスに関与しているため、医療支出が増加しています。したがって、今後数年間にグリコミクスの研究、診断、治療に対するニーズが非常に高まると予測されます。

世界の医療支出は増加の一途をたどることが予測され、グリコミクス市場も大きく成長する見込みです。グリコミクスの革新と進歩は、医療研究開発への投資の増加によって促進されると予測されます。研究センター、製薬企業、学術機関が連携することで、この部門の進歩が期待されます。こうした戦略的提携は、学際的な協力、リソースの共有、知識の交換を促進し、画期的な発見や糖鎖ベースの治療薬の創出に有利な雰囲気を作り出します。個別化医療が具体化するにつれ、糖鎖研究と診断への需要が急増すると予測されます。糖鎖プロファイリングは、疾患や治療反応に関する個別化された知見を提供する上で大きな可能性を秘めており、特に、各患者固有の生物学的プロファイルに合わせて医療療法をカスタマイズすることが重視されるようになっていることを考慮すると、その可能性は大きいです。したがって、グリコミクスは患者中心の医療ソリューションの開発に大きく寄与し、さらなる成長に拍車をかける可能性を秘めています。

当レポートでは、世界のグリコミクス/グリコバイオロジー市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢と見通しなどを提供しています。

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界のグリコミクス/グリコバイオロジー市場の見通し（2017年～2031年）

  • 市場規模と予測
    • 金額
    • 数量
  • 製品タイプ別
    • 酵素
    • キット
    • 試薬、化学品
    • 炭水化物
    • 器具
  • 用途別
    • 創薬、開発
    • 診断
    • その他
  • エンドユーザー別
    • 学術研究機関
    • 製薬企業、バイオテクノロジー企業
    • 臨床検査室
    • 開発業務受託機関
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • 南米
    • 中東・アフリカ
  • 市場シェア：企業別（2023年）

第5章 世界のグリコミクス/グリコバイオロジー市場の見通し：地域別（2017年～2031年）

  • 北米
    • 市場規模と予測
    • 製品タイプ別
    • 用途別
    • エンドユーザー別
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • フランス
    • イタリア
    • 英国
    • ロシア
    • オランダ
    • スペイン
    • トルコ
    • ポーランド
  • アジア太平洋
    • インド
    • 中国
    • 日本
    • オーストラリア
    • ベトナム
    • 韓国
    • インドネシア
    • フィリピン
  • 南米
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • 南アフリカ

第6章 市場マッピング（2023年）

  • 製品タイプ別
  • 用途別
  • エンドユーザー別
  • 地域別

第7章 マクロ環境と産業構造

  • 需給分析
  • 輸入輸出分析
  • バリューチェーン分析
  • PESTEL分析
  • ポーターのファイブフォース分析

第8章 市場力学

  • 成長促進要因
  • 成長抑制要因（課題、抑制要因）

第9章 規制枠組みとイノベーション

  • 臨床試験
  • 特許情勢
  • 規制当局の承認
  • イノベーション/新技術

第10章 主要企業の情勢

  • マーケットリーダー上位5社の競合マトリクス
  • マーケットリーダー上位5社の市場収益の分析（2023年）
  • 合併と買収/合弁事業（該当する場合）
  • SWOT分析（市場企業5社）
  • 特許分析（該当する場合）

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Agilent Technologies, Inc.
  • Waters Corporation
  • New England Biolabs France SASU
  • Bruker Corporation
  • Takara Bio USA, Inc.
  • Danaher Corporation
  • Bio-Techne Corporation
  • Shimadzu Corporation

第14章 戦略的推奨

第15章 当社について、免責事項

図表

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Glycomics/Glycobiology Market, By Value, in USD Billion, 2017-2031F
  • Figure 2. Global Glycomics/Glycobiology Market, By Volume, in Million Units, 2017-2031F
  • Figure 3. Global Glycomics/Glycobiology Market Share (%), By Product Type, 2017-2031F
  • Figure 4. Global Glycomics/Glycobiology Market Share (%), By Application, 2017-2031F
  • Figure 5. Global Glycomics/Glycobiology Market Share (%), By End-user, 2017-2031F
  • Figure 6. Global Glycomics/Glycobiology Market Share (%), By Region, 2017-2031F
  • Figure 7. North America Glycomics/Glycobiology Market, By Value, in USD Billion, 2017-2031F
  • Figure 8. North America Glycomics/Glycobiology Market, By Volume, in Million Units, 2017-2031F
  • Figure 9. North America Glycomics/Glycobiology Market Share (%), By Product Type, 2017-2031F
  • Figure 10. North America Glycomics/Glycobiology Market Share (%), By Application, 2017-2031F
  • Figure 11. North America Glycomics/Glycobiology Market Share (%), By End-user, 2017-2031F
  • Figure 12. North America Glycomics/Glycobiology Market Share (%), By Country, 2017-2031F
  • Figure 13. United States Glycomics/Glycobiology Market, By Value, in USD Billion, 2017-2031F
  • Figure 14. United States Glycomics/Glycobiology Market, By Volume, in Million Units, 2017-2031F
  • Figure 15. United States Glycomics/Glycobiology Market Share (%), By Product Type, 2017-2031F
  • Figure 16. United States Glycomics/Glycobiology Market Share (%), By Application, 2017-2031F
  • Figure 17. United States Glycomics/Glycobiology Market Share (%), By End-user, 2017-2031F
  • Figure 18. Canada Glycomics/Glycobiology Market, By Value, in USD Billion, 2017-2031F
  • Figure 19. Canada Glycomics/Glycobiology Market, By Volume, in Million Units, 2017-2031F
  • Figure 20. Canada Glycomics/Glycobiology Market Share (%), By Product Type, 2017-2031F
  • Figure 21. Canada Glycomics/Glycobiology Market Share (%), By Application, 2017-2031F
  • Figure 22. Canada Glycomics/Glycobiology Market Share (%), By End-user, 2017-2031F
  • Figure 23. Mexico Glycomics/Glycobiology Market, By Value, in USD Billion, 2017-2031F
  • Figure 24. Mexico Glycomics/Glycobiology Market, By Volume, in Million Units, 2017-2031F
  • Figure 25. Mexico Glycomics/Glycobiology Market Share (%), By Product Type, 2017-2031F
  • Figure 26. Mexico Glycomics/Glycobiology Market Share (%), By Application, 2017-2031F
  • Figure 27. Mexico Glycomics/Glycobiology Market Share (%), By End-user, 2017-2031F
  • Figure 28. Europe Glycomics/Glycobiology Market, By Value, in USD Billion, 2017-2031F
  • Figure 29. Europe Glycomics/Glycobiology Market, By Volume, in Million Units, 2017-2031F
  • Figure 30. Europe Glycomics/Glycobiology Market Share (%), By Product Type, 2017-2031F
  • Figure 31. Europe Glycomics/Glycobiology Market Share (%), By Application, 2017-2031F
  • Figure 32. Europe Glycomics/Glycobiology Market Share (%), By End-user, 2017-2031F
  • Figure 33. Europe Glycomics/Glycobiology Market Share (%), By Country, 2017-2031F
  • Figure 34. Germany Glycomics/Glycobiology Market, By Value, in USD Billion, 2017-2031F
  • Figure 35. Germany Glycomics/Glycobiology Market, By Volume, in Million Units, 2017-2031F
  • Figure 36. Germany Glycomics/Glycobiology Market Share (%), By Product Type, 2017-2031F
  • Figure 37. Germany Glycomics/Glycobiology Market Share (%), By Application, 2017-2031F
  • Figure 38. Germany Glycomics/Glycobiology Market Share (%), By End-user, 2017-2031F
  • Figure 39. France Glycomics/Glycobiology Market, By Value, in USD Billion, 2017-2031F
  • Figure 40. France Glycomics/Glycobiology Market, By Volume, in Million Units, 2017-2031F
  • Figure 41. France Glycomics/Glycobiology Market Share (%), By Product Type, 2017-2031F
  • Figure 42. France Glycomics/Glycobiology Market Share (%), By Application, 2017-2031F
  • Figure 43. France Glycomics/Glycobiology Market Share (%), By End-user, 2017-2031F
  • Figure 44. Italy Glycomics/Glycobiology Market, By Value, in USD Billion, 2017-2031F
  • Figure 45. Italy Glycomics/Glycobiology Market, By Volume, in Million Units, 2017-2031F
  • Figure 46. Italy Glycomics/Glycobiology Market Share (%), By Product Type, 2017-2031F
  • Figure 47. Italy Glycomics/Glycobiology Market Share (%), By Application, 2017-2031F
  • Figure 48. Italy Glycomics/Glycobiology Market Share (%), By End-user, 2017-2031F
  • Figure 49. United Kingdom Glycomics/Glycobiology Market, By Value, in USD Billion, 2017-2031F
  • Figure 50. United Kingdom Glycomics/Glycobiology Market, By Volume, in Million Units, 2017-2031F
  • Figure 51. United Kingdom Glycomics/Glycobiology Market Share (%), By Product Type, 2017-2031F
  • Figure 52. United Kingdom Glycomics/Glycobiology Market Share (%), By Application, 2017-2031F
  • Figure 53. United Kingdom Glycomics/Glycobiology Market Share (%), By End-user, 2017-2031F
  • Figure 54. Russia Glycomics/Glycobiology Market, By Value, in USD Billion, 2017-2031F
  • Figure 55. Russia Glycomics/Glycobiology Market, By Volume, in Million Units, 2017-2031F
  • Figure 56. Russia Glycomics/Glycobiology Market Share (%), By Product Type, 2017-2031F
  • Figure 57. Russia Glycomics/Glycobiology Market Share (%), By Application, 2017-2031F
  • Figure 58. Russia Glycomics/Glycobiology Market Share (%), By End-user, 2017-2031F
  • Figure 59. Netherlands Glycomics/Glycobiology Market, By Value, in USD Billion, 2017-2031F
  • Figure 60. Netherlands Glycomics/Glycobiology Market, By Volume, in Million Units, 2017-2031F
  • Figure 61. Netherlands Glycomics/Glycobiology Market Share (%), By Product Type, 2017-2031F
  • Figure 62. Netherlands Glycomics/Glycobiology Market Share (%), By Application, 2017-2031F
  • Figure 63. Netherlands Glycomics/Glycobiology Market Share (%), By End-user, 2017-2031F
  • Figure 64. Spain Glycomics/Glycobiology Market, By Value, in USD Billion, 2017-2031F
  • Figure 65. Spain Glycomics/Glycobiology Market, By Volume, in Million Units, 2017-2031F
  • Figure 66. Spain Glycomics/Glycobiology Market Share (%), By Product Type, 2017-2031F
  • Figure 67. Spain Glycomics/Glycobiology Market Share (%), By Application, 2017-2031F
  • Figure 68. Spain Glycomics/Glycobiology Market Share (%), By End-user, 2017-2031F
  • Figure 69. Turkey Glycomics/Glycobiology Market, By Value, in USD Billion, 2017-2031F
  • Figure 70. Turkey Glycomics/Glycobiology Market, By Volume, in Million Units, 2017-2031F
  • Figure 71. Turkey Glycomics/Glycobiology Market Share (%), By Product Type, 2017-2031F
  • Figure 72. Turkey Glycomics/Glycobiology Market Share (%), By Application, 2017-2031F
  • Figure 73. Turkey Glycomics/Glycobiology Market Share (%), By End-user, 2017-2031F
  • Figure 74. Poland Glycomics/Glycobiology Market, By Value, in USD Billion, 2017-2031F
  • Figure 75. Poland Glycomics/Glycobiology Market, By Volume, in Million Units, 2017-2031F
  • Figure 76. Poland Glycomics/Glycobiology Market Share (%), By Product Type, 2017-2031F
  • Figure 77. Poland Glycomics/Glycobiology Market Share (%), By Application, 2017-2031F
  • Figure 78. Poland Glycomics/Glycobiology Market Share (%), By End-user, 2017-2031F
  • Figure 79. South America Glycomics/Glycobiology Market, By Value, in USD Billion, 2017-2031F
  • Figure 80. South America Glycomics/Glycobiology Market, By Volume, in Million Units, 2017-2031F
  • Figure 81. South America Glycomics/Glycobiology Market Share (%), By Product Type, 2017-2031F
  • Figure 82. South America Glycomics/Glycobiology Market Share (%), By Application, 2017-2031F
  • Figure 83. South America Glycomics/Glycobiology Market Share (%), By End-user, 2017-2031F
  • Figure 84. South America Glycomics/Glycobiology Market Share (%), By Country, 2017-2031F
  • Figure 85. Brazil Glycomics/Glycobiology Market, By Value, in USD Billion, 2017-2031F
  • Figure 86. Brazil Glycomics/Glycobiology Market, By Volume, in Million Units, 2017-2031F
  • Figure 87. Brazil Glycomics/Glycobiology Market Share (%), By Product Type, 2017-2031F
  • Figure 88. Brazil Glycomics/Glycobiology Market Share (%), By Application, 2017-2031F
  • Figure 89. Brazil Glycomics/Glycobiology Market Share (%), By End-user, 2017-2031F
  • Figure 90. Argentina Glycomics/Glycobiology Market, By Value, in USD Billion, 2017-2031F
  • Figure 91. Argentina Glycomics/Glycobiology Market, By Volume, in Million Units, 2017-2031F
  • Figure 92. Argentina Glycomics/Glycobiology Market Share (%), By Product Type, 2017-2031F
  • Figure 93. Argentina Glycomics/Glycobiology Market Share (%), By Application, 2017-2031F
  • Figure 94. Argentina Glycomics/Glycobiology Market Share (%), By End-user, 2017-2031F
  • Figure 95. Asia-Pacific Glycomics/Glycobiology Market, By Value, in USD Billion, 2017-2031F
  • Figure 96. Asia-Pacific Glycomics/Glycobiology Market, By Volume, in Million Units, 2017-2031F
  • Figure 97. Asia-Pacific Glycomics/Glycobiology Market Share (%), By Product Type, 2017-2031F
  • Figure 98. Asia-Pacific Glycomics/Glycobiology Market Share (%), By Application, 2017-2031F
  • Figure 99. Asia-Pacific Glycomics/Glycobiology Market Share (%), By End-user, 2017-2031F
  • Figure 100. Asia-Pacific Glycomics/Glycobiology Market Share (%), By Country, 2017-2031F
  • Figure 101. India Glycomics/Glycobiology Market, By Value, in USD Billion, 2017-2031F
  • Figure 102. India Glycomics/Glycobiology Market, By Volume, in Million Units, 2017-2031F
  • Figure 103. India Glycomics/Glycobiology Market Share (%), By Product Type, 2017-2031F
  • Figure 104. India Glycomics/Glycobiology Market Share (%), By Application, 2017-2031F
  • Figure 105. India Glycomics/Glycobiology Market Share (%), By End-user, 2017-2031F
  • Figure 106. China Glycomics/Glycobiology Market, By Value, in USD Billion, 2017-2031F
  • Figure 107. China Glycomics/Glycobiology Market, By Volume, in Million Units, 2017-2031F
  • Figure 108. China Glycomics/Glycobiology Market Share (%), By Product Type, 2017-2031F
  • Figure 109. China Glycomics/Glycobiology Market Share (%), By Application, 2017-2031F
  • Figure 110. China Glycomics/Glycobiology Market Share (%), By End-user, 2017-2031F
  • Figure 111. Japan Glycomics/Glycobiology Market, By Value, in USD Billion, 2017-2031F
  • Figure 112. Japan Glycomics/Glycobiology Market, By Volume, in Million Units, 2017-2031F
  • Figure 113. Japan Glycomics/Glycobiology Market Share (%), By Product Type, 2017-2031F
  • Figure 114. Japan Glycomics/Glycobiology Market Share (%), By Application, 2017-2031F
  • Figure 115. Japan Glycomics/Glycobiology Market Share (%), By End-user, 2017-2031F
  • Figure 116. Australia Glycomics/Glycobiology Market, By Value, in USD Billion, 2017-2031F
  • Figure 117. Australia Glycomics/Glycobiology Market, By Volume, in Million Units, 2017-2031F
  • Figure 118. Australia Glycomics/Glycobiology Market Share (%), By Product Type, 2017-2031F
  • Figure 119. Australia Glycomics/Glycobiology Market Share (%), By Application, 2017-2031F
  • Figure 120. Australia Glycomics/Glycobiology Market Share (%), By End-user, 2017-2031F
  • Figure 121. Vietnam Glycomics/Glycobiology Market, By Value, in USD Billion, 2017-2031F
  • Figure 122. Vietnam Glycomics/Glycobiology Market, By Volume, in Million Units, 2017-2031F
  • Figure 123. Vietnam Glycomics/Glycobiology Market Share (%), By Product Type, 2017-2031F
  • Figure 124. Vietnam Glycomics/Glycobiology Market Share (%), By Application, 2017-2031F
  • Figure 125. Vietnam Glycomics/Glycobiology Market Share (%), By End-user, 2017-2031F
  • Figure 126. South Korea Glycomics/Glycobiology Market, By Value, in USD Billion, 2017-2031F
  • Figure 127. South Korea Glycomics/Glycobiology Market, By Volume, in Million Units, 2017-2031F
  • Figure 128. South Korea Glycomics/Glycobiology Market Share (%), By Product Type, 2017-2031F
  • Figure 129. South Korea Glycomics/Glycobiology Market Share (%), By Application, 2017-2031F
  • Figure 130. South Korea Glycomics/Glycobiology Market Share (%), By End-user, 2017-2031F
  • Figure 131. Indonesia Glycomics/Glycobiology Market, By Value, in USD Billion, 2017-2031F
  • Figure 132. Indonesia Glycomics/Glycobiology Market, By Volume, in Million Units, 2017-2031F
  • Figure 133. Indonesia Glycomics/Glycobiology Market Share (%), By Product Type, 2017-2031F
  • Figure 134. Indonesia Glycomics/Glycobiology Market Share (%), By Application, 2017-2031F
  • Figure 135. Indonesia Glycomics/Glycobiology Market Share (%), By End-user, 2017-2031F
  • Figure 136. Philippines Glycomics/Glycobiology Market, By Value, in USD Billion, 2017-2031F
  • Figure 137. Philippines Glycomics/Glycobiology Market, By Volume, in Million Units, 2017-2031F
  • Figure 138. Philippines Glycomics/Glycobiology Market Share (%), By Product Type, 2017-2031F
  • Figure 139. Philippines Glycomics/Glycobiology Market Share (%), By Application, 2017-2031F
  • Figure 140. Philippines Glycomics/Glycobiology Market Share (%), By End-user, 2017-2031F
  • Figure 141. Middle East & Africa Glycomics/Glycobiology Market, By Value, in USD Billion, 2017-2031F
  • Figure 142. Middle East & Africa Glycomics/Glycobiology Market, By Volume, in Million Units, 2017-2031F
  • Figure 143. Middle East & Africa Glycomics/Glycobiology Market Share (%), By Product Type, 2017-2031F
  • Figure 144. Middle East & Africa Glycomics/Glycobiology Market Share (%), By Application, 2017-2031F
  • Figure 145. Middle East & Africa Glycomics/Glycobiology Market Share (%), By End-user, 2017-2031F
  • Figure 146. Middle East & Africa Glycomics/Glycobiology Market Share (%), By Country, 2017-2031F
  • Figure 147. Saudi Arabia Glycomics/Glycobiology Market, By Value, in USD Billion, 2017-2031F
  • Figure 148. Saudi Arabia Glycomics/Glycobiology Market, By Volume, in Million Units, 2017-2031F
  • Figure 149. Saudi Arabia Glycomics/Glycobiology Market Share (%), By Product Type, 2017-2031F
  • Figure 150. Saudi Arabia Glycomics/Glycobiology Market Share (%), By Application, 2017-2031F
  • Figure 151. Saudi Arabia Glycomics/Glycobiology Market Share (%), By End-user, 2017-2031F
  • Figure 152. UAE Glycomics/Glycobiology Market, By Value, in USD Billion, 2017-2031F
  • Figure 153. UAE Glycomics/Glycobiology Market, By Volume, in Million Units, 2017-2031F
  • Figure 154. UAE Glycomics/Glycobiology Market Share (%), By Product Type, 2017-2031F
  • Figure 155. UAE Glycomics/Glycobiology Market Share (%), By Application, 2017-2031F
  • Figure 156. UAE Glycomics/Glycobiology Market Share (%), By End-user, 2017-2031F
  • Figure 157. South Africa Glycomics/Glycobiology Market, By Value, in USD Billion, 2017-2031F
  • Figure 158. South Africa Glycomics/Glycobiology Market, By Volume, in Million Units, 2017-2031F
  • Figure 159. South Africa Glycomics/Glycobiology Market Share (%), By Product Type, 2017-2031F
  • Figure 160. South Africa Glycomics/Glycobiology Market Share (%), By Application, 2017-2031F
  • Figure 161. South Africa Glycomics/Glycobiology Market Share (%), By End-user, 2017-2031F
  • Figure 162. By Product Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 163. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 164. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 165. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023
目次
Product Code: MX11493

Global glycomics/glycobiology market is projected to witness a CAGR of 14.93% during the forecast period 2024-2031F, growing from USD 1.92 billion in 2023 to USD 5.85 billion in 2031F. The market has experienced significant growth in recent years and is expected to maintain a strong pace of expansion in the coming years.

Glycans' abnormal structures or glycosylation patterns are increasingly being connected to various diseases, like autoimmune disorders, diabetes, and cancer, as researchers continue to explore the intricacies of glycans and their interactions with other biomolecules. As a result, the discipline of glycomics aims to clarify glycan structures, functions, and effects on health and illness, signaling possible advances in identifying, managing, and creating new drugs. Numerous interconnected variables are driving the worldwide glycomics market's growth trajectory. Glycomomics has gained significant attention as a potential means of diagnosing and treating diseases, including diabetes and cancer, linked to aberrant glycosylation patterns. Due to these state-of-the-art tools, researchers may delve further into the complexity of glycans and their functional significance in both health and disease.

The importance of glycomics in influencing the direction of healthcare is further highlighted by the paradigm shift towards personalized medicine. Glycan profiling has the potential to significantly increase the effectiveness and accuracy of medical interventions by offering tailored insights into customized treatment plans. The patient-centered approach to healthcare emphasizes how important glycomics is to progress towards patient-centered therapeutic options. The rapidly growing biopharmaceutical sector is realizing how important glycan analysis is to creating biologics. For instance, on January 30, 2024, Navinci Diagnostics AB Corp, the leader in breakthrough in situ proximity ligation assay-based solutions, and Vector Laboratories, the pioneer of innovative proteomic and glycomic research solutions, announced the signing of an agreement. The collaboration aims to create innovative biomarker discovery techniques that will identify protein glycosylation in tissue samples for the first time.

Increasing Expenditure on Healthcare to Propel the Market

The steady rise in healthcare spending across the globe is providing a significant boom to the global glycomics market. Both public and commercial organizations are contributing more money to healthcare research and development projects, which drives investments in fields such as glycomics. An improved understanding of glycans' critical function in different biological processes and their consequences for human health is reflected in increased financial commitment. More emphasis is being given to comprehending and treating complicated diseases, many of which involve glycan-related processes, resulting from boosted healthcare spending. Thus, it is anticipated that in the upcoming years, there will be a huge need for glycomics research, diagnostics, and treatments.

The worldwide healthcare expenditure is expected to continue rising, and the glycomics market is expected to rise significantly. Innovation and advances in glycomics are expected to be fueled by the increased investment in healthcare research and development. Research centers, pharmaceutical corporations, and academic institutions working together are expected to propel the sector forward. These strategic alliances promote interdisciplinary cooperation, resource sharing, and exchange of knowledge, which creates an atmosphere that is favorable for ground-breaking discoveries and creation of glycan-based therapeutics. The demand for glycomics research and diagnostics is predicted to rise sharply as personalized medicine takes shape. Glycan profiling has great potential in offering individualized insights into diseases and treatment responses, particularly considering the growing emphasis on customizing medical therapies to each patient's unique biological profile. Therefore, glycomics has the potential to significantly contribute to the development of patient-centric healthcare solutions and spur additional growth.

The pharmaceutical industry is paying more attention to the medicinal potential of glycans in addition to research and diagnostics. With tremendous potential for treating numerous diseases, the field of glycan-based therapy development is a rapidly expanding drug discovery and development area. Improved patient outcomes, addressing unmet medical needs, and collaborative initiatives between academia and industry are anticipated to accelerate the translation of glycomics research into clinically relevant medicines. Due to the rising healthcare costs, more money is being spent on research and development, and the concerted efforts of players in the government, business, and academic sectors, the worldwide glycomics market is expected to rise significantly. For instance, Thermo Fisher Scientific Inc. and TransMIT GmbH Center for Mass Spectrometric Developments announced a co-marketing agreement in June 2022 to further promote the use of mass spectrometry imaging (MSI) platforms for spatial multi-omics applications in clinical and pharmaceutical laboratories.

Expanding Biopharmaceutical Research to Expand the Market

Over the past few decades, biopharmaceutical research has rapidly evolved, with a primary focus on creating novel medicines for a range of diseases and disorders. Glycomics is one of the fields to study that has attracted a lot of interest lately. Glycans are essential to many biological functions. Growth in the global glycomics market is significant as biopharmaceutical research is growing. Biopharmaceutical research is at the forefront of medical discovery and development, especially in the areas of immunology, infectious illnesses, and oncology. Glycomics is becoming more important to researchers and pharmaceutical businesses as a means of comprehending causes of illnesses and developing personalized treatments.

Glycomics research in the biopharmaceutical industry is growing due to several variables. Advances in personalized medicine necessitate a deeper comprehension of the distinct biomarkers, such as glycans, exclusive to each patient. Glycomics can customize treatments according to a patient's unique glycan profile, increasing therapeutic efficacy and reducing adverse effects. Cancer treatment has been transformed by immunotherapies and glycomics, which is essential for comprehending the glycan-based interactions that cancer cells have with the immune system. Glycan-targeted immunotherapies are being actively investigated by researchers to enhance the efficacy of cancer treatment. Since glycans are important in many infections, they are interesting targets for vaccine development.

Glycan-based vaccines are being funded by biopharmaceutical companies to fight infectious diseases such as COVID-19, HIV, and influenza. Glycans are becoming more valuable as disease indicators. The discovery of glycan biomarkers that can help with early illness detection, disease monitoring, and therapy response assessment is being driven by biopharmaceutical research. The market for glycomics goods and services has grown significantly due to glycomics' growing significance in biopharmaceutical research. Technologies, including mass spectrometry, liquid chromatography, and glycan analysis kits, are included in the global glycomics market. It includes services such as glycoprotein characterization and glycan profiling. Innovation in glycomics research is being fostered by partnerships among research centers, pharmaceutical corporations, and university institutions. These collaborations aim to hasten the advancement of glycan-based treatments and diagnostics.

For instance, Bruker Corporation reported advances in glycoproteomics, immunopeptidomics, and other 4D proteomics workflows enabled by Collision Cross Section (CCS) on March 11, 2024. Rapid advancements in glycomics, peptidomics, and deep, at-scale proteomics research solutions from Bruker Corporation enhance its other industry-leading, high-performance life science technologies for the post-genomic era. When combined, they provide vital insights into disease biology and biomarkers for the development of next-generation molecular diagnostics and pharmaceuticals, as well as post-genomic molecular and cell biology research

Increasing Dominance of the Drug Discovery Segment

Developing novel medications is becoming more necessary as chronic disease burdens rise. Glycans are essential for biological functions such as cell-to-cell contact, making them crucial for creating new drugs. Consequently, glycan chains are changed to create medications. For instance, hyaluronan, a naturally occurring glycosaminoglycan disaccharide unit, has several medicinal uses. It is crucial for treating osteoarthritis and is used in wound care following surgery. Studying glycans at the nanoscale can help with the development of vaccinations, medication delivery strategies, and biomolecular therapies for viruses and infectious disorders. Using glycoprotein expression systems and genetic engineering methods, glycan-based self-adjuvanted vaccines can be developed to enhance immunogenicity and vaccine response. Glycobiology is, therefore, crucial to creating vaccines, which fuels the market's expansion. The Mizutani Foundation for Glycoscience received 119 proposals for research grants from 28 different countries in February 2022. Following a thorough assessment of the projects' potential, scientific and social quality, and viability, the Foundation chose to fund 14 projects with grants totaling about USD 0.51 million. Therefore, Grants and approvals are anticipated to stimulate glycobiology research and development, accelerating the segment's growth.

North America to Dominate the Glycomics/Glycobiology Market

Opportunities for North America are anticipated to increase due to the growing prevalence of chronic diseases in the United States, government funding programs, and increased research and development. Cold Spring Harbour Laboratory Press (CSHL Press), a publisher of scientific books, journals, and electronic media, launched a new initiative in September 2022 to give access to the rapidly expanding subject of glycobiology in the United States. Support for the grant for CSHL Press comes from InterVenn Biosciences, a clinical technology business using glycoproteomics to change the face of healthcare. It suggests glycobiology is receiving more attention, which is anticipated to drive market expansion in the United States in the upcoming years.

One of the developers of cutting-edge proteome and glycobiology solutions, Vector Laboratories, Inc. launched a new location in Newark, California, in March 2022. These immunofluorescence (IF) kits are fully integrated to detect glycan expression in tissue slices and allow the profiling and characterization of complex glycans in biological systems. Glycan research is becoming more popular as more academics are interested in studying glycobiology because of its possible influence on significant areas of medical research, such as oncology. Therefore, the market under study is anticipated to grow rapidly throughout the projected period due to the abovementioned factors.

Future Market Scenario (2024 - 2031F)

One of the main factors contributing to the anticipated growth of the glycomics/glycobiology market is the increasing prevalence of chronic disorders such as cancer and diabetes and the increasing popularity of personalized medicine approaches. A rising population and sedentary lifestyles are expected to propel the market growth in the forecast period. Given that technology is advancing, we can expect cutting-edge technology. Players in the market are expanding at an unparalleled rate, introducing cost-effective and efficient technologies. For instance, using unbiased lipidomics, glycomics, and metabolomics tissue imaging in conjunction with HiPLEX-IHC peptide code antibody probes from AmberGen, Bruker Corporation introduced a unique MALDI HiPLEX-IHC tissue imaging solution for timsTOF flex in April 2022.

Key Players Landscape and Outlook

Several companies are expanding their business by planning and adopting new strategies. They are complying with new strategic initiatives regarding the launches of newly developed products, to help researchers and to increase their presence in the market. New product launches, agreements based on contracts, acquisitions and mergers, investments and partnerships are a few ways through which they are trying to achieve the same.

As part of a larger investment, by 2025, Merck KGaA will invest over USD 320.93 million (EUR 300 million) in a new Life Science Research Center at its headquarters in Darmstadt in 2023. The facility's research efforts will be concentrated on finding solutions of mRNA applications, antibody synthesis, and other biotechnological products. Establishing operations in 2027 will further strengthen Merck's commitment to scientific progress.

Table of Contents

1. Research Methodology

2. Project Scope and Definitions

3. Executive Summary

4. Global Glycomics/Glycobiology Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2. By Product Type
    • 4.2.1. Enzymes
      • 4.2.1.1. Glycosidases
      • 4.2.1.2. Transferases
      • 4.2.1.3. Others
    • 4.2.2. Kits
      • 4.2.2.1. Glycan Releasing Kits
      • 4.2.2.2. Glycan Labelling Kits
      • 4.2.2.3. Glycan Purification Kits
      • 4.2.2.4. Others
    • 4.2.3. Reagents and Chemicals
    • 4.2.4. Carbohydrates
      • 4.2.4.1. Oligosaccharides
      • 4.2.4.2. Monosaccharides
    • 4.2.5. Instruments
      • 4.2.5.1. Mass Spectrometry Instruments
      • 4.2.5.2. Chromatography Instruments
      • 4.2.5.3. Arrays
      • 4.2.5.4. Others
  • 4.3. By Application
    • 4.3.1. Drug Discovery and Development
    • 4.3.2. Diagnostics
    • 4.3.3. Others
  • 4.4. By End-user
    • 4.4.1. Academic and Research Institutes
    • 4.4.2. Pharmaceutical and Biotechnology Companies
    • 4.4.3. Clinical Laboratories
    • 4.4.4. Contract Research Organisations
  • 4.5. By Region
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia-Pacific
    • 4.5.4. South America
    • 4.5.5. Middle East and Africa
  • 4.6. By Company Market Share (%), 2023

5. Global Glycomics/Glycobiology Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. By Value
      • 5.1.1.2. By Volume
    • 5.1.2. By Product Type
      • 5.1.2.1. Enzymes
        • 5.1.2.1.1. Glycosidases
        • 5.1.2.1.2. Transferases
        • 5.1.2.1.3. Others
      • 5.1.2.2. Kits
        • 5.1.2.2.1. Glycan Releasing Kits
        • 5.1.2.2.2. Glycan Labelling Kits
        • 5.1.2.2.3. Glycan Purification Kits
        • 5.1.2.2.4. Others
      • 5.1.2.3. Reagents and Chemicals
      • 5.1.2.4. Carbohydrates
        • 5.1.2.4.1. Oligosaccharides
        • 5.1.2.4.2. Monosaccharides
      • 5.1.2.5. Instruments
        • 5.1.2.5.1. Mass Spectrometry Instruments
        • 5.1.2.5.2. Chromatography Instruments
        • 5.1.2.5.3. Arrays
        • 5.1.2.5.4. Others
    • 5.1.3. By Application
      • 5.1.3.1. Drug Discovery and Development
      • 5.1.3.2. Diagnostics
      • 5.1.3.3. Others
    • 5.1.4. By End-user
      • 5.1.4.1. Academic and Research Institutes
      • 5.1.4.2. Pharmaceutical and Biotechnology Companies
      • 5.1.4.3. Clinical Laboratories
      • 5.1.4.4. Contract Research Organisations
    • 5.1.5. United States*
      • 5.1.5.1. Market Size & Forecast
        • 5.1.5.1.1. By Value
        • 5.1.5.1.2. By Volume
      • 5.1.5.2. By Product Type
        • 5.1.5.2.1. Enzymes
          • 5.1.5.2.1.1. Glycosidases
          • 5.1.5.2.1.2. Transferases
          • 5.1.5.2.1.3. Others
        • 5.1.5.2.2. Kits
          • 5.1.5.2.2.1. Glycan Releasing Kits
          • 5.1.5.2.2.2. Glycan Labelling Kits
          • 5.1.5.2.2.3. Glycan Purification Kits
          • 5.1.5.2.2.4. Others
        • 5.1.5.2.3. Reagents and Chemicals
        • 5.1.5.2.4. Carbohydrates
          • 5.1.5.2.4.1. Oligosaccharides
          • 5.1.5.2.4.2. Monosaccharides
        • 5.1.5.2.5. Instruments
          • 5.1.5.2.5.1. Mass Spectrometry Instruments
          • 5.1.5.2.5.2. Chromatography Instruments
          • 5.1.5.2.5.3. Arrays
          • 5.1.5.2.5.4. Others
      • 5.1.5.3. By Application
        • 5.1.5.3.1. Drug Discovery and Development
        • 5.1.5.3.2. Diagnostics
        • 5.1.5.3.3. Others
      • 5.1.5.4. By End-user
        • 5.1.5.4.1. Academic and Research Institutes
        • 5.1.5.4.2. Pharmaceutical and Biotechnology Companies
        • 5.1.5.4.3. Clinical Laboratories
        • 5.1.5.4.4. Contract Research Organisations
    • 5.1.6. Canada
    • 5.1.7. Mexico

All segments will be provided for all regions and countries covered

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. Asia-Pacific
    • 5.3.1. India
    • 5.3.2. China
    • 5.3.3. Japan
    • 5.3.4. Australia
    • 5.3.5. Vietnam
    • 5.3.6. South Korea
    • 5.3.7. Indonesia
    • 5.3.8. Philippines
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
  • 5.5. Middle East and Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Product Type
  • 6.2. By Application
  • 6.3. By End-user
  • 6.4. By Region

7. Macro Environment and Industry Structure

  • 7.1. Demand Supply Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Clinical Trials
  • 9.2. Patent Landscape
  • 9.3. Regulatory Approvals
  • 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (By Value, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Thermo Fisher Scientific Inc.
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products and Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus and Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. Merck KGaA
  • 13.3. Agilent Technologies, Inc.
  • 13.4. Waters Corporation
  • 13.5. New England Biolabs France SASU
  • 13.6. Bruker Corporation
  • 13.7. Takara Bio USA, Inc.
  • 13.8. Danaher Corporation
  • 13.9. Bio-Techne Corporation
  • 13.10. Shimadzu Corporation

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14. Strategic Recommendations

15. About Us and Disclaimer